Achilles Therapeutics updates Phase I/IIa trial of clonal neoantigen reactive T cells in advanced NSCLC and melanoma, reports improved VELOS™ manufacturing and stronger cash position.

Achilles Therapeutics reports interim Phase I/IIa data on clonal neoantigen reactive T cells (cNeT) in advanced NSCLC and melanoma. The VELOS™ manufacturing process has improved, delivering higher cNeT doses, and protocols have been updated to evaluate enhanced host conditioning benefits, with data expected in H2 2024. Strong cash position of $131.5m supports operations through 2025.

April 04, 2024
3 Articles

Further Reading